Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-505842-24-00 | EU Trial (CTIS) Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis.
The study will enroll approximately 1000 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups for TAK-279, placebo, or apremilast in a ratio of 2:1:1 which will remain undisclosed to the patient and investigator during the study (unless there is an urgent medical need):
This multi-center trial will be conducted worldwide. The overall time to participate in this study is 69 weeks. Participants will go through a screening process to make sure they meet the rules for taking part in the study. This will take up to 35 days. If participants meet the study rules, they will be treated for up to 60 weeks. There will be a safety follow-up visit 4 weeks after their last day of treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TAK-279 | Experimental |
| |
| Placebo | Placebo Comparator |
| |
| Apremilast | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TAK-279 | Drug | Specified drug on specified days. |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1. | Baseline, Week 16 |
| Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16 Comparing TAK-279 Against Placebo | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported. | Baseline, Week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving 90% Improvement from Baseline in PASI (PASI-90) at Week 16 Comparing TAK-279 Against Placebo | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Total Dermatology | Birmingham | Alabama | 35205 | United States | ||
| Cahaba Dermatology Skin Health Center |
Not provided
| Label | URL |
|---|---|
| To obtain more information on the study, click here/on this link | View source |
Not provided
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Not provided
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Specified drug on specified days. |
|
| Apremilast | Drug | Specified drug on specified days. |
|
| Baseline, Week 16 |
| Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Placebo | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' will include all participants who score a 0. | Week 16 |
| Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Placebo | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported. | Week 16 |
| Percentage of Participants Achieving a Scalp-specific Physician's Global Assessment (ssPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo | ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening. | Baseline, Week 16 |
| Percentage of Participants Achieving PASI-75 at Week 4 Comparing TAK-279 Against Placebo | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 75% improvement in PASI score relative to baseline PASI score will be reported. | Week 4 |
| Percentage of Participants with a Baseline Dermatology Life Quality Index (DLQI) Score ≥2 who Achieve DLQI Score of 0 or 1 at Week 16 Comparing TAK-279 Against Placebo | The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). | Week 16 |
| Percentage of Participants With a Baseline Psoriasis Symptoms and Signs Diary (PSSD) ≥1 who Achieve Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Placebo | The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease. | Week 16 |
| Change from Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 Among Participants With Nail Involvement at Baseline Comparing TAK-279 Against Placebo | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis. | Baseline, Week 16 |
| Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo | Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement. | Week 16 |
| Percentage Change from Baseline in BSA Affected by Psoriasis at Week 16 Comparing TAK-279 Against Placebo | Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement. | Week 16 |
| Percentage of Participants Achieving a Physician's Global Assessment (PGA) of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease From Baseline at Week 16 Comparing TAK-279 Against Placebo | PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1. | Baseline, Week 16 |
| Change from Baseline in DLQI at Week 16 Comparing TAK-279 Against Placebo | The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). It will be evaluated for participants with a baseline DLQI score ≥2. | Baseline, Week 16 |
| Change from Baseline in the Short Form-36 Health Survey (SF-36) Version 2 Scores at Week 16 Comparing TAK-279 Against Placebo | The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the physical component summary (PCS) and mental component summary (MCS), will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL. | Baseline, Week 16 |
| Change from Baseline in the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores at Week 16 Comparing TAK-279 Against Placebo | EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health. | Baseline, Week 16 |
| Change in Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) Questionnaire Scores at Week 16 Comparing TAK-279 Against Placebo | The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. | Week 16 |
| Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. Higher scores indicate worsening. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1. | Baseline to Week 16 |
| Percentage of Participants Achieving PASI-75 at Week 16 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported. | Week 16 |
| Percentage of Participants Achieving PASI-90 at Week 16 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported. | Week 16 |
| Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1. | Baseline to Week 24 |
| Percentage of Participants Achieving PASI-75 at Week 24 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported. | Week 24 |
| Percentage of Participants Achieving PASI-90 at Week 24 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported. | Week 24 |
| Change from Baseline in Weekly Mean PSSD Symptom Score at Week 16 Comparing TAK-279 Against Apremilast | The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease. | Baseline to Week 16 |
| Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Apremilast | ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening. | Baseline to Week 16 |
| Percentage of Participants Achieving PASI-100 at Week 16 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported. | Week 16 |
| Percentage of Participants Achieving PASI-100 at Week 24 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported. | Week 24 |
| Percentage of Participants Achieving an sPGA of Clear (0) at Week 16 Comparing TAK-279 Against Apremilast | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0. | Week 16 |
| Percentage of Participants with a Baseline DLQI Score ≥2 who Achieve DLQI Score of 0/1 at Week 16 Comparing TAK-279 Against Apremilast | The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). | Week 16 |
| Percentage of Participants With a Baseline PSSD ≥1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 16 Comparing TAK-279 Against Apremilast | The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease. | Week 16 |
| Change from Baseline in NAPSI Among Participants With Nail Involvement at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each nail will be scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores indicate more severe psoriasis. | Baseline, Weeks 16 and 24 |
| Percentage of Participants Achieving an ssPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 24 Comparing TAK-279 Against Apremilast | ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening. | Baseline to Week 24 |
| Change from Baseline in DLQI at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). | Baseline, Weeks 16 and 24 |
| Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement. | Baseline, Weeks 16 and 24 |
| Percent Change from Baseline in BSA Affected by Psoriasis at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | Psoriasis BSA will be assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represents 1% BSA. The sum of handprints equates to the total surface area of involvement. | Baseline, Weeks 16 and 24 |
| Percentage of Participants Achieving an sPGA of Clear (0) at Week 24 Comparing TAK-279 Against Apremilast | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0. | Week 24 |
| Percentage of Participants With a Baseline DLQI Score ≥2 who Achieve a DLQI Score of 0/1 at Week 24 Comparing TAK-279 Against Apremilast | The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's QoL during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicate: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). | Week 24 |
| Percentage of Participants With a Baseline PSSD ≥1 who Achieve a Weekly Mean PSSD Symptom Score of 0 at Week 24 Comparing TAK-279 Against Apremilast | The PSSD is an 11-item validated questionnaire that assesses symptoms (itch, pain, stinging, burning, and skin tightness) and participant-observable signs (skin dryness, cracking, scaling, shedding/flaking, redness, and bleeding) of moderate-to-severe plaque psoriasis. These symptoms and signs will be evaluated by asking participants to assign a numerical score representing of worst intensity over the last 24-hour on a scale from 0 to 10, with 0 indicating absence of symptoms or signs and 10 indicating worst imaginable symptoms or signs. The PSSD is a composite score calculated based on the scores for each question that can range between 0 and 100. A higher score indicates more severe disease. | Week 24 |
| Change from Baseline in ssPGA at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions will be evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicate worsening. | Baseline, Weeks 16 and 24 |
| Percentage of Participants Achieving a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease From Baseline at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | PGA is a 5-point scale and a score of 0 to 4 should be assigned, based on the category that best describes the severity of active psoriasis of the participant's hands and/or feet (palmoplantar), where 0=clear and 4=severe. Higher scores indicate worsening of severity. It will be evaluated for participants with the presence of active hand or foot psoriasis on Day 1. | Baseline, Weeks 16 and 24 |
| Change from Baseline in SF-36 Version 2 Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | The SF-36 is a self-administered, validated questionnaire designed to measure generic health-related QoL. This 36-item questionnaire measures 8 domains, including physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health, physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Two summary scores, including the PCS and MCS, will be calculated ranging from 0 (worst) to 100 (best). Higher scores indicate better QoL. | Baseline, Weeks 16 and 24 |
| Change from Baseline in the EQ-5D-5L Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | EQ-5D-5L includes 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 5 response levels for each domain (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). The scores in the 5 dimensions will be summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health; 0=a health state equivalent to death, and 1=perfect health. | Baseline, Weeks 16 and 24 |
| Change from Baseline in the WPAI-PSO Scores at Weeks 16 and 24 Comparing TAK-279 Against Apremilast | The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score will be expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. | Baseline, Weeks 16 and 24 |
| Percentage of Participants Achieving an sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Weeks 24 and 40 Comparing TAK-279 Against Apremilast | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1. | Baseline, Weeks 24 and 40 |
| Percentage of Participants Achieving PASI-75 at Weeks 24 and 40 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported. | Weeks 24 and 40 |
| Percentage of Participants Achieving PASI-90 at Weeks 24 and 40 Comparing TAK-279 Against Apremilast | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported. | Weeks 24 and 40 |
| Time to Relapse for PASI-75 Responders at Week 40 Comparing TAK-279 Against Placebo | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported. | Up to Week 60 |
| Percentage of Participants With Maintenance of PASI-75 Response at Week 60 Comparing TAK-279 Against Placebo | PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported. | Week 60 |
| Percentage of Participants with Maintenance of sPGA of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 60 Comparing TAK-279 Against Placebo | The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1. | Baseline to Week 60 |
| Percentage of Participants With a Disease Relapse Comparing TAK-279 Against Placebo | Relapse is defined as a percent change from baseline in PASI score that is at least 50% worse than that observed at Week 40. PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Higher scores indicate worsening. | Week 40 |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI) | TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product. An AESI (serious or nonserious) is an adverse event of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator may be appropriate. | Up to week 69 |
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | Up to week 69 |
| Number of Participants With Clinically Significant Laboratory Values | Up to week 69 |
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings | Up to week 69 |
| Hoover |
| Alabama |
| 35244-2111 |
| United States |
| Medical Dermatology Specialists | Phoenix | Arizona | 85006-2722 | United States |
| Noble Clinical Research | Tucson | Arizona | 85704-7892 | United States |
| Johnson Dermatology Clinic | Fort Smith | Arkansas | 72916-6103 | United States |
| Burke Pharmaceutical Research | Hot Springs | Arkansas | 71913-6475 | United States |
| Zenith Research, Inc. | Beverly Hills | California | 90211-1705 | United States |
| UNISON Clinical Trials (Shahram Jacobs md inc.) | Encino | California | 91436-2428 | United States |
| First OC Dermatology Research Inc. | Fountain Valley | California | 92708-3701 | United States |
| Long Beach Research Institute, LLC | Long Beach | California | 90805-4587 | United States |
| Metropolis Dermatology Downtown LA - Probity - PPDS | Los Angeles | California | 90017-5310 | United States |
| Northridge Clinical Trials | Northridge | California | 91325-4122 | United States |
| TCR Medical Corporation | San Diego | California | 92123-1523 | United States |
| University Clinical Trials | San Diego | California | 92123 | United States |
| Dermatology Institute and Skin Care Center | Santa Monica | California | 90404-2216 | United States |
| Revival Research Corporation - Florida - ClinEdge - PPDS | Doral | Florida | 33122-1902 | United States |
| Florida Academic Centers Research | Miami | Florida | 33136-1003 | United States |
| San Marcus Research Clinic Inc | Miami Lakes | Florida | 33014-5602 | United States |
| FXM Research Miramar | Miramar | Florida | 33027-4714 | United States |
| Lenus Research & Medical Group | Sweetwater | Florida | 33172-2741 | United States |
| Advanced Clinical Research Institute (ACRI) - Florida | Tampa | Florida | 33607-6429 | United States |
| Olympian Clinical Research - 6331 Memorial Hwy | Tampa | Florida | 33615 | United States |
| Divine Dermatology and Aesthetics, LLC | Atlanta | Georgia | 30315-2042 | United States |
| Advanced Medical Research, PC | Atlanta | Georgia | 30342-1418 | United States |
| Skin Care Physicians of Georgia | Macon | Georgia | 31217-3861 | United States |
| NorthShore Medical Group Dermatology - Skokie | Skokie | Illinois | 60077-1049 | United States |
| DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location | Clarksville | Indiana | 47129-2201 | United States |
| Skin Sciences, PLLC | Louisville | Kentucky | 40217-1444 | United States |
| DS Research of Kentucky | Louisville | Kentucky | 40241-6162 | United States |
| Dermatology & Advanced Aesthetics | Lake Charles | Louisiana | 70605-1213 | United States |
| Lawrence J Green, MD LLC | Rockville | Maryland | 20850-6363 | United States |
| Allcutis Research LLC | Beverly | Massachusetts | 01915 | United States |
| Beacon Clinical Research LLC | Brockton | Massachusetts | 02301 | United States |
| David Fivenson MD Dermatology PLLC | Ann Arbor | Michigan | 48103-9746 | United States |
| University of Michigan Hospital - 1500 E Medical Center Dr | Ann Arbor | Michigan | 48109-5360 | United States |
| Oakland Hills Dermatology - 3400 Auburn Rd | Auburn Hills | Michigan | 48326-3396 | United States |
| Minnesota Clinical Study Center | Fridley | Minnesota | 55432-3134 | United States |
| Skin Specialists PC | Omaha | Nebraska | 68144 | United States |
| Vivida Dermatology - Flamingo Rd - Probity - PPDS | Las Vegas | Nevada | 89119-5190 | United States |
| ALLCUTIS Research, LLC. | Portsmouth | New Hampshire | 03801-03804 | United States |
| Psoriasis Treatment Center of Central New Jersey | East Windsor | New Jersey | 08520 | United States |
| Mount Sinai Doctors -234 E 85th St | New York | New York | 10029-6504 | United States |
| Sadick Research Group | New York | New York | 10075-0385 | United States |
| Derm Research Center of NY | Stony Brook | New York | 11790 | United States |
| Montefiore Dermatology - BRANY - PPDS | The Bronx | New York | 10467-1402 | United States |
| Duke Dermatology Clinic | Durham | North Carolina | 27710-4000 | United States |
| The Skin Surgery Center for Clinical Research - Objective Health - PPDS | Winston-Salem | North Carolina | 27103-7109 | United States |
| Wake Forest Baptist Health Department of Dermatology - 4618 Country Club Rd | Winston-Salem | North Carolina | 27157-0001 | United States |
| ClinOhio Research Services | Columbus | Ohio | 43213-4445 | United States |
| Wright State Physicians | Fairborn | Ohio | 45324 | United States |
| Apex Clinical Research Center | Mayfield Heights | Ohio | 44124-4005 | United States |
| Oregon Medical Research Center PC | Portland | Oregon | 97239-4501 | United States |
| University of Pittsburgh Medical Center-3601 5th Ave | Pittsburgh | Pennsylvania | 15213-3403 | United States |
| Cumberland Skin Center for Clinical Research - Objective Health - PPDS | Hermitage | Tennessee | 37076-3497 | United States |
| Tennessee Clinical Research Center | Nashville | Tennessee | 37215-2888 | United States |
| Arlington Research Center | Arlington | Texas | 76011-3800 | United States |
| UT Physicians Dermatology - Bellaire Station | Bellaire | Texas | 77401-3535 | United States |
| Modern Research Associates | Dallas | Texas | 75231-6077 | United States |
| North Texas Center for Clinical Research | Frisco | Texas | 75034 | United States |
| Austin Institute for Clinical Research, Inc. - Pflugerville - ClinEdge - PPDS | Pflugerville | Texas | 78660-6148 | United States |
| Texas Dermatology and Laser Specialists | San Antonio | Texas | 78218-3128 | United States |
| Dermatology Clinical Research Center of San Antonio | San Antonio | Texas | 78229-3409 | United States |
| Houston Center for Clinical Research, LLC | Sugar Land | Texas | 77479-1001 | United States |
| Center For Clinical Studies, LTD. LLP - 451 N Texas Ave | Webster | Texas | 77598-4927 | United States |
| Center For Clinical Studies,LTD. LLP - 451 N Texas Ave | Webster | Texas | 77598-4927 | United States |
| Virginia Clinical Research - 6160 Kempsville Cir | Norfolk | Virginia | 23507 | United States |
| Conexa Investigación Clínica S.A. | Buenos Aires | C1012 | Argentina |
| STAT Research S.A. | Buenos Aires | C1023AAB | Argentina |
| Instituto de Neumonologia y Dermatologia | Buenos Aires | C1425BEA | Argentina |
| Centro de Investigacion Clínica - CEDIC | Ciudad Autónomade Buenos Aires | C1060ABN | Argentina |
| Centro de Investigaciones Médicas Tucumán - PPDS | San Miguel de Tucumán | T4000 | Argentina |
| Medical Center Unimed EOOD | Sevlievo | Gabrovo | 5400 | Bulgaria |
| Medical Center Asklepii OOD | Dupnitsa | Kyustendil | 2600 | Bulgaria |
| MBAL Skin Systems, Doganovo | Elin Pelin | Sofia | 2115 | Bulgaria |
| Diagnostic and Consulting Center Aleksandrovska EOOD | Sofia | Sofia-Grad | 1431 | Bulgaria |
| Diagnostic Consultative Centre - Focus-5 - LZIP EOOD | Sofia | Sofia-Grad | 1463 | Bulgaria |
| Medical Center Hera EOOD | Sofia | Sofia-Grad | 1510 | Bulgaria |
| Diagnostic Consultative Center XXVIII - Sofia - EOOD | Sofia | Sofia-Grad | 1592 | Bulgaria |
| Ambulatory for Specialized Medical Care- Group Practice in Dermatology - Clinic EuroDerma OOD | Sofia | Sofia-Grad | 1606 | Bulgaria |
| Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia | Sofia | Sofia-Grad | 1606 | Bulgaria |
| MC Comac Medical - IRN - PPDS | Sofia | Sofia-Grad | 1612 | Bulgaria |
| Multiprofile Hospital for Active Treatment - Dobrich AD | Dobrich | 9300 | Bulgaria |
| Multiprofile Hospital For Active Treatment Dr Tota Venkova | Gabrovo | 5300 | Bulgaria |
| Diagnostic Consultative Center Sveti Georgi EOOD | Haskovo | 6300 | Bulgaria |
| Medical Center Medconsult Pleven OOD | Pleven | 5800 | Bulgaria |
| Medical Center Exacta Medica - Vasil Levski 60 | Pleven | 5801 | Bulgaria |
| University Multiprofile Hospital for Active Treatment -Dr. Georgi Stranski -Gen. V. Vazov Str 91 | Pleven | Bulgaria |
| Dermatology Research Institute, Inc. - Probity - PPDS | Calgary | Alberta | T3A 2N1 | Canada |
| Alberta DermaSurgery Centre - Probity - PPDS | Edmonton | Alberta | T6G 1C2 Canada | Canada |
| VIDA Dermatology - Probity - PPDS | Edmonton | Alberta | T6H 4J8 | Canada |
| CaRe Clinic-Red Deer | Red Deer | Alberta | T4N 7C3 | Canada |
| Wiseman Dermatology Research Inc. - Probity - PPDS | Winnipeg | Manitoba | R3E 0V9 | Canada |
| Brunswick Dermatology Centre - Probity - PPDS | Fredericton | New Brunswick | E3B 1G9 | Canada |
| Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity - PPDS | Hamilton | Ontario | L8L 3C3 | Canada |
| Dermatrials Research | Hamilton | Ontario | L8N 1Y2 | Canada |
| DermEffects - Probity - PPDS | London | Ontario | N6H 5L5 | Canada |
| Lynderm Research Inc - Probity - PPDS | Markham | Ontario | L3P 1X3 | Canada |
| DermEdge Research - Probity - PPDS | Mississauga | Ontario | L4Y 4C5 | Canada |
| The Centre for Clinical Trials Inc. - Probity - PPDS | Oakville | Ontario | L6J 7W5 | Canada |
| Oshawa Clinic-117 King St | Oshawa | Ontario | L1R 1R7 | Canada |
| SKiN Centre for Dermatology - Peterborough - Probity - PPDS | Peterborough | Ontario | K9J 1Z2 | Canada |
| Centre For Dermatology and Cosmetic Surgery - Probity - PPDS | Richmond Hill | Ontario | L4B 1M5 | Canada |
| Dr. S. K. Siddha Medicine Professional Corporation - Probity - PPDS | Richmond Hill | Ontario | L4C 9M7 | Canada |
| Canadian Dermatology Centre - Probity - PPDS | Toronto | Ontario | M3B 0A7 | Canada |
| Toronto Research Centre - Probity - PPDS | Toronto | Ontario | M3H 5Y8 | Canada |
| Alliance Clinical Trials - Probity - PPDS | Waterloo | Ontario | N2J 1C4 | Canada |
| XLR8 Medical Research - Probity - PPDS | Windsor | Ontario | N8X 3V6 | Canada |
| Siena Medical Research | Westmount | Quebec | H3Z 2S6 | Canada |
| Skinsense Medical Research - 411 2nd Ave N - Probity - PPDS | Saskatoon | Saskatchewan | S7K 0H6 | Canada |
| China-Japan Friendship Hospital | Beijing | Beijing Municipality | 100029 | China |
| Guangdong Provincial People's Hospital | Guangzhou | Guangdong | 510080 | China |
| Henan Provincial People's Hospital | Zhengzhou | Henan | 450003 | China |
| Tongji Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan | Hubei | 430030 | China |
| The Third Xiangya Hospital of Central South University | Changsha | Hunan | 410013 | China |
| The First Affiliated Hospital With Nanjing Medical University(Jiangsu Province Hospital) | Nanjing | Jiangsu | 210029 | China |
| Affiliated Hospital of Jiangsu University | Zhenjiang | Jiangsu | 212001 | China |
| The Second Affiliated Hospital of Nanchang University | Nanchang | Jiangxi | 330008 | China |
| First Hospital of Shanxi Medical University | Taiyuan | Shanxi | 030001 | China |
| West China Hospital Sichuan University | Chengdu | Sichuan | 610041 | China |
| The Second Affiliated Hospital of Kunming Medical University | Kunming | Yunnan | 650000 | China |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine - Qingchun Campus | Hangzhou | Zhejiang | 310016 | China |
| Huashan Hospital Fudan University - PPDS | Shanghai | 200040 | China |
| Dermamedica, s.r.o. - Kozni Ambulance Nachod | Náchod | Hradec Králové Region | 547 01 | Czechia |
| Nemocnice AGEL Novy Jicin a.s | Nový Jičín | Moravian-Silesian Region | 741 01 | Czechia |
| CCR Ostrava s.r.o. | Ostrava | Moravian-Silesian Region | 702 00 | Czechia |
| Praglandia s.r.o. | Prague | Ohio | 150 00 | Czechia |
| Dermskin s.r.o. | Olomouc | Olomouc Region | 779 00 | Czechia |
| CLINTRIAL s.r.o. | Prague | Praha, Hlavní Mesto | 100 00 | Czechia |
| Pratia Brno s.r.o. - PRATIA - PPDS | Brno | South Moravian | 602 00 | Czechia |
| Pratia Pardubice a.s. - PRATIA - PPDS | Pardubice | 530 02 | Czechia |
| Fakultni nemocnice Kralovske Vinohrady | Prague | 100 34 | Czechia |
| Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS | Prague | 110 00 | Czechia |
| Centre Hospitalier Le Mans | Le Mans | Ohio | 72037 | France |
| AP-HM- Hôpital de La Timone | Marseille | 13885 | France |
| Hôpital Charles Nicolle-1 Rue de Germont | Rouen | 76031 | France |
| Fachklinik Bad Bentheim | Bad Bentheim | Lower Saxony | 48455 | Germany |
| Klinische Forschung Dresden GmbH (KFGN) - PRATIA - PPDS | Dresden | Saxony | 01069 | Germany |
| Praxis fur Dermatologie and Venerologie | Dresden | Saxony | 01097 | Germany |
| SRH Wald-Klinikum Gera GmbH | Gera | Thuringia | 07548 | Germany |
| FutureMeds - Berlin - PPDS | Berlin | 10629 | Germany |
| Dermatologikum Hamburg | Hamburg | 20354 | Germany |
| Medizinisches Versorgungszentrum DermaKiel GmbH | Kiel | 24148 | Germany |
| Hospital A.Syggros | Athens | Attica | 161 21 | Greece |
| University General Hospital ''ATTIKON'' | Chaïdári | Attica | 124 62 | Greece |
| University Hospital of Ioannina | Loannina | Loannina | 455 00 | Greece |
| Hospital Of Skin And Venereal Diseases of Thessaloniki | Thessaloniki | 546 43 | Greece |
| Papageorgiou General Hospital of Thessaloniki | Thessaloniki | 564 29 | Greece |
| Szegedi Tudomanyegyetem | Szeged | Csongrád megye | 6720 | Hungary |
| Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus | Debrecen | Hajdú-Bihar | 4032 | Hungary |
| Allergo-Derm Bakos Kft- Szolnok-Baross utca 20 | Szolnok | Jász-Nagykun-Szolnok | 5000 | Hungary |
| Somogy Varmegyei Kaposi Mor Oktato Korhaz | Kaposvár | Somogy County | 7400 | Hungary |
| Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz | Szombathely | Vas County | 9700 | Hungary |
| Pécsi Tudomanyegyetem - Vasvari Pal u. | Pécs | 7632 | Hungary |
| Hadassah Medical Center- Ein Kerem - PPDS | Jerusalem | Jerusalem | 9112002 | Israel |
| The Chaim Sheba Medical Center - PPDS | Ramat Gan | Tel Aviv | 52621 | Israel |
| Tel Aviv Sourasky Medical Center Ichilov - PPDS 27004 | Tel Aviv | Tel Aviv | 64239 | Israel |
| HaEmek Medical Center | Afula | 18101 | Israel |
| Rabin Medical Center - PPDS | Petah Tikva | 49100 | Israel |
| Adoria | Riga | Ohio | LV-1011 | Latvia |
| Smite Aija doctor practice in dermatology, venerology | Talsi | Talsu Aprinkis | LV-3201 | Latvia |
| Semigallia | Kuldīga | LV-3301 | Latvia |
| Riga 1st Hospital | Riga | LV-1001 | Latvia |
| Health Center 4, Center of Diagnostics | Riga | LV-1003 | Latvia |
| J. Kisis | Riga | LV-1003 | Latvia |
| Veseliba un estetika | Riga | LV-1009 | Latvia |
| Health Center 4, Clinic of Dermatology | Riga | LV-1013 | Latvia |
| Solumed Centrum Medyczne | Poznan | Greater Poland Voivodeship | 60-101 | Poland |
| Twoja Przychodnia PCM | Poznan | Greater Poland Voivodeship | 61-293 | Poland |
| Centrum Medyczne ALL-MED | Krakow | Lesser Poland Voivodeship | 30-033 | Poland |
| Krakowskie Centrum Medyczne - FutureMeds - PPDS | Krakow | Lesser Poland Voivodeship | 31-501 | Poland |
| WroMedica | Wroclaw | Lower Silesian Voivodeship | 51-685 | Poland |
| Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska | Lublin | Lublin Voivodeship | 20-573 | Poland |
| Twoja Przychodnia Nowosolskie Centrum Medyczne sp. z o.o | Nowa Sól | Lubusz Voivodeship | 67-100 | Poland |
| Centrum Terapii Wspolczesnej | Lódz | Lódzkie | 90-338 | Poland |
| ClinMedica Research | Skierniewice | Lódzkie | 96-100 | Poland |
| ETG Siedlce - PPDS | Siedlce | Masovian Voivodeship | 08-110 | Poland |
| RCMed Oddzial Sochaczew | Sochaczew | Masovian Voivodeship | 96-500 | Poland |
| Clinical Research Group Sp. z o.o | Warsaw | Masovian Voivodeship | 01-142 | Poland |
| AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie | Warsaw | Masovian Voivodeship | 02-672 | Poland |
| ETG Warszawa - PPDS | Warsaw | Masovian Voivodeship | 02-677 | Poland |
| FutureMeds - Targowek - PPDS | Warsaw | Masovian Voivodeship | 03-291 | Poland |
| MICS Centrum Medyczne Torun - MICS - PPDS | Torun | Ohio | 87-100 | Poland |
| NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik | Bialystok | Podlaskie Voivodeship | 15-351 | Poland |
| Centrum Medyczne Chojnice - PRATIA - PPDS | Chojnice | Pomeranian Voivodeship | 89-600 | Poland |
| Centrum Badan Klinicznych PI-House sp. z o.o. | Gdansk | Pomeranian Voivodeship | 80-546 | Poland |
| AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni | Gdynia | Pomeranian Voivodeship | 81-537 | Poland |
| AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Katowicach | Katowice | Silesian Voivodeship | 40-040 | Poland |
| Centrum Medyczne Angelius Provita | Katowice | Silesian Voivodeship | 40-611 | Poland |
| Pro Familia Altera Sp. z o.o. | Katowice | Silesian Voivodeship | 40-648 | Poland |
| Centrum Uslug Medycznych MaxMed | Bochnia | 32-700 | Poland |
| Ambulatorium Barbara Bazela | Elblag | 82-300 | Poland |
| Globe Badania Kliniczne Spólka z o.o. - Klodzko | Klodzko Dolnoslaskie | 57-300 | Poland |
| MCM Krakow - PRATIA - PPDS | Krakow | 30-727 | Poland |
| Diamond Clinic | Krakow | 31-559 | Poland |
| ETG Lublin - PPDS | Lublin | 20-314 | Poland |
| ETYKA Osrodek Badan Klinicznych | Olsztyn | 10-117 | Poland |
| DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski, s.c. | Osielsko | 86-031 | Poland |
| Royalderm | Warsaw | Poland |
| dermMEDICA Sp. z o.o | Wroclaw | 51-503 | Poland |
| Dermedic Jacek Zdybski | Ostrowiec Świętokrzyski | Świętokrzyskie Voivodeship | 27-400 | Poland |
| Ostrowieckie Centrum Medyczne | Ostrowiec Świętokrzyski | Świętokrzyskie Voivodeship | 27-400 | Poland |
| GCM Medical Group, PSC -62 Calle Jose Marti | San Juan | 00909-3004 | Puerto Rico |
| Hospital Universitario Germans Trias i Pujol | Badalona | Barcelona | 08915 | Spain |
| Hospital de Manises | Manises | Valencia | 46940 | Spain |
| Hospital de La Santa Creu i Sant Pau | Barcelona | 08041 | Spain |
| Hospital Universitario de Gran Canaria Doctor Negrin | Las Palmas de Gran Canaria | 35010 | Spain |
| Hospital Clinico San Carlos | Madrid | 28040 | Spain |
| Hospital Universitario La Paz - PPDS | Madrid | 28046 | Spain |
| Velocity Clinical Research, High Wycombe - PPDS | High Wycombe | Buckinghamshire | HP11 2QW | United Kingdom |
| 4 Medical Clinical Solutions (4MCS) Swinton - PPDS | Ilford | Essex | IG1 4HP | United Kingdom |
| Accellacare of Yorkshire | Chorley | Lancashire | PR7 7NA | United Kingdom |
| Salford Royal Hospital - PPDS | Salford | Lancashire | M6 8HD | United Kingdom |
| Whipps Cross Hospital | London | London, City of | E11 1NR | United Kingdom |
| Accellacare of Northamptonshire | Harrow | Middlesex | HA1 3UJ | United Kingdom |
| Velocity Clinical Research, North London - PPDS | London | Middlesex | N12 8BU | United Kingdom |
| Accellacare - North London Clinical Studies Centre | Northwood | Middlesex | HA6 2RN | United Kingdom |
| St Luke's Hospital | Bradford | West Yorkshire | BD5 0NA | United Kingdom |
| ID | Term |
|---|---|
| C505730 | apremilast |
Not provided
Not provided
Not provided